Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PICS: Certolizumab Pegol in RA
NCT01213017Phase 3Completed
- Sponsor
- Oklahoma Medical Research Foundation
- Start
- Sep 2010
- Primary completion
- Jan 2011
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 3 trial of certolizumab pegol in rheumatoid arthritis (RA), sponsored by Oklahoma Medical Research Foundation. Started Sep 2010; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01213017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01213017.